Filing Flows › Black Diamond Therapeutics (BDTX) › Takeover & LBO
Is Black Diamond Therapeutics (BDTX) a takeover target?
A leveraged buyout does not work for Black Diamond Therapeutics on its latest figures: the figures a buyout model needs (revenue, EBITDA, the share count and the price) are not all on file. Latest signal (2026-11-06): Black Diamond Sales Rise 12% as Clarus Weighs Strategic Alternatives.
Why a leveraged buyout does not fit
The buyout model needs Black Diamond Therapeutics' revenue, EBITDA, share count and share price; not all of them are on file, so it gives no buyout price.
What a takeover could cost
Takeovers in its sector paid a median premium of 35% over the share price before the deal (the middle half 22% to 45%), according to the 15 merger proxies and tender-offer responses on EDGAR that state a premium.
Rumors and deal signals
- 2026-11-06 · news · Black Diamond Sales Rise 12% as Clarus Weighs Strategic Alternatives
- 2026-10-26 · news · ApCo and Black Diamond set timeline for acquisition talks
Black Diamond Therapeutics' latest quarter
Black Diamond Therapeutics, Q1 2025: revenue $70.0M, operating margin 77.9%, net earnings $56.5M, operating cash flow $53.4M. The chart follows the revenue to costs, profit and cash.
Questions
Is Black Diamond Therapeutics being acquired?
The latest signal on file is from 2026-11-06: Black Diamond Sales Rise 12% as Clarus Weighs Strategic Alternatives. A headline is not a deal; Filing Flows lists the news, 8-K filings and 13D filings about a sale.
Could private equity buy Black Diamond Therapeutics?
A leveraged buyout does not work for Black Diamond Therapeutics on its latest figures: the figures a buyout model needs (revenue, EBITDA, the share count and the price) are not all on file. The model gives no buyout price until they are.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.